Skip to main content

Tumor Markers and Their Relevance in the Design of Radioimmunoimaging Experiments

  • Conference paper
Radiolabeled Monoclonal Antibodies for Imaging and Therapy

Part of the book series: NATO ASI Series ((NSSA,volume 152))

  • 77 Accesses

Abstract

The dream of an immuno-oncologist is to define precise epitopes of tumor-specific markers. That of a nuclear medicine physician is to identify a reliable, reproducible, system not only for the imaging of tumors but also to prognosticate on the course of disease in the patient and between these two expectations is the realm of immunoscintigraphy. Histopathologic and serologic identification of neoplasia as well as the monitoring of their treatment can be effected through their tumor-associated markers. The latter have been classified as oncofetal protein antigens, enzymes, hormones, polyamines, or unusual or unexpected carbohydrate antigens. The production of the markers varies during the natural progression of malignancy and may correlate with its aggressiveness. Despite the complexities related to the conditions of appearance and disappearance of such markers in patient sera, certain tumor markers may be more constant in their behavior. An excellent summation of the status of such markers in clinical practice has been presented by Colnaghi et al. (1). Our group has been interested in carbohydrate expression on cancer cells which display dramatic changes in the composition and architecture of cell surface glycoproteins and glycolipids and which are recognized by the immune system. These cell surface carbohydrate antigens are known to participate in important cell-cell interactions and the regulation of cell growth and differentiation (2,3). Aberrant expression of carbohydrate antigens on malignant cells is well documented and may play an important role in maintaining the malignant phenotype (4). Moreover, the expression of new carbohydrate determinants on malignant cells, found only in very low concentrations on some normal cells, may represent important markers 1) to study their role in malignancy, 2) for early detection of cancer, 3) for the management of cancer patients, 4) for prognosis and 5) for cancer immunotherapy. Table 1 summarizes some of the important carbohydrate antigens which have been associated with a number of human cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. M. I. Colnaghi, G. L. Buraggi, and M. Ghiona, “Markers for Diagnosis and Monitoring of Human Cancer,” Serono Symposia, Vol. 46, Academic Press, New York (1982).

    Google Scholar 

  2. S. I. Hakomori, and R. Kannagi, Glycosphingolipids as Tumor-Associated and Differentiation Markers, J. N. C. I. 71:231 (1983).

    CAS  Google Scholar 

  3. T. Feizi, Demonstration by Monoclonal Antibodies that Carbohydrate Structures of Glycoproteins and Glycolipids are Onco-Developmental Antigens, Nature 314:53 (1985).

    Article  PubMed  CAS  Google Scholar 

  4. G. Yogeeswaran, Cell Surface Glycolipids and Glycoproteins in Malignant Transformation, Adv. Cancer Res. 38:289 (1983).

    Article  PubMed  CAS  Google Scholar 

  5. A. Noujaim, S. Selvaraj, M. Suresh, G. MacLean, D. Williams, C. Turner, D. Haines, and B. Longenecker, A Molecular Approach to Immunoscintigraphy: A Study of the T-Antigen Conformation on the Surface of Tumors, Nuklearmedizin, 26:1–6 (1986).

    Google Scholar 

  6. A. Noujaim, B. Longenecker, M. Suresh, C. Turner, T. Sykes, and G. MacLean, Characterization and Selection Criteria of Monoclonal Antibodies for Tumor Imaging Studies, This book, preceding paper.

    Google Scholar 

  7. G. F. Springer et al., General Carcinoma Autoantigens, Science 224:1198 (1984).

    Article  PubMed  CAS  Google Scholar 

  8. M. V. Pimm, A. C. Perkins, and R. W. Baldwin, Differences in Tumor and Normal Tissue Concentrations of Iodine- and Indium-Labeled Monoclonal Antibody. II. Biodistribution studies in Mice and Human Tumor Xenografts, Eur. J. Nucl. Med. 11:300 (1985).

    Article  PubMed  CAS  Google Scholar 

  9. P. L. Hagan, S. E. Halpern, A. Chen, L. Krishnan, J. Frincke, R. M. Bartholomew, G. S. David, and D. Carlo, In Vivo Kinetics of Radiolabeled Monoclonal Anti-CEA Antibodies in Animal Models, J. Nucl. Med. 26:1418 (1985).

    PubMed  CAS  Google Scholar 

  10. D. A. Goodwin, C. F. Meares, M. J. McCall, M. K. Haseman, M. McTigue, C. I. Diamanti, and W. Chaovapony, Chelate Conjugates of Monoclonal Antibodies for Imaging Lymphoid Structures in the Mouse, J. Nucl. Med. 26:493 (1985).

    PubMed  CAS  Google Scholar 

  11. A. G. Cooper, J. F. Codington, and M. C. Brown, In Vivo Release of glycoprotein I from the Ha Subline of TA3 Murine Tumor into Ascites Fluid and Serum, Proc. Natl. Acad. Sci. 71:1224 (1974).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer Science+Business Media New York

About this paper

Cite this paper

Noujaim, A.A., Longenecker, B.M., Suresh, M.R., MacLean, G.D., Turner, C.J., Sykes, T.R. (1988). Tumor Markers and Their Relevance in the Design of Radioimmunoimaging Experiments. In: Srivastava, S.C. (eds) Radiolabeled Monoclonal Antibodies for Imaging and Therapy. NATO ASI Series, vol 152. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5538-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-5538-0_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-5540-3

  • Online ISBN: 978-1-4684-5538-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics